Cargando…
Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051295/ https://www.ncbi.nlm.nih.gov/pubmed/36992241 http://dx.doi.org/10.3390/vaccines11030657 |
_version_ | 1785014851143204864 |
---|---|
author | Fuchs, Teresa Appelt, Dorothea Ellemunter, Helmut |
author_facet | Fuchs, Teresa Appelt, Dorothea Ellemunter, Helmut |
author_sort | Fuchs, Teresa |
collection | PubMed |
description | People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published data of patients with solid organ transplantation without CF as underlying disease. Antibodies against the spike receptor-binding domain were measured within the routine visits at the CF Centre in Innsbruck, Austria, after the second and third doses of SARS-CoV-2 mRNA vaccines. We report on 13 adult CF patients who are recipients of solid organ transplant, including five CF-LI and eight CF-LU. Overall, 69% had measurable antibody response after two, and 83% after three doses of SARS-CoV-2 vaccines. In CF-LI, positive serological response amounted to 100% after two and three doses, while CF-LU showed only a 50% and a 71% response rate, respectively. Clear differences are seen between the CF-LI and CF-LU groups in our cohort, with worse response rate for lung transplant recipients. Immune response between CF-LI and CF-LU, therefore, must be considered in a differentiated manner, and the importance of booster vaccination is once more emphasized with these data. |
format | Online Article Text |
id | pubmed-10051295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100512952023-03-30 Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? Fuchs, Teresa Appelt, Dorothea Ellemunter, Helmut Vaccines (Basel) Communication People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published data of patients with solid organ transplantation without CF as underlying disease. Antibodies against the spike receptor-binding domain were measured within the routine visits at the CF Centre in Innsbruck, Austria, after the second and third doses of SARS-CoV-2 mRNA vaccines. We report on 13 adult CF patients who are recipients of solid organ transplant, including five CF-LI and eight CF-LU. Overall, 69% had measurable antibody response after two, and 83% after three doses of SARS-CoV-2 vaccines. In CF-LI, positive serological response amounted to 100% after two and three doses, while CF-LU showed only a 50% and a 71% response rate, respectively. Clear differences are seen between the CF-LI and CF-LU groups in our cohort, with worse response rate for lung transplant recipients. Immune response between CF-LI and CF-LU, therefore, must be considered in a differentiated manner, and the importance of booster vaccination is once more emphasized with these data. MDPI 2023-03-14 /pmc/articles/PMC10051295/ /pubmed/36992241 http://dx.doi.org/10.3390/vaccines11030657 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Fuchs, Teresa Appelt, Dorothea Ellemunter, Helmut Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title | Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title_full | Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title_fullStr | Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title_full_unstemmed | Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title_short | Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? |
title_sort | is there a difference in immune response to sars-cov-2 vaccination between liver and lung transplant patients with cystic fibrosis? |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051295/ https://www.ncbi.nlm.nih.gov/pubmed/36992241 http://dx.doi.org/10.3390/vaccines11030657 |
work_keys_str_mv | AT fuchsteresa isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis AT appeltdorothea isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis AT ellemunterhelmut isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis |